Qiagen N.V. Q1 FY2025 earnings call

Management Statement and Operational Highlights

• Q1 Performance: Qiagen exceeded net sales and adjusted earnings outlook. Net sales were $483 million, up 7% at CER. Adjusted diluted EPS was $0.50 at CER.
• Portfolio Highlights:
  • QIAstat had double-digit sales growth from new panel launches and instrument placements.
  • QuantiFERON had double-digit sales growth, driving transition to blood-based TB testing.
  • QIAcuity continued momentum in oncology, infectious diseases, etc.
  • QDI extended leadership in bioinformatics, with a new data center in Australia.
  • Sample Technologies preparing new instrument launches for expanded automation.
• Capital Allocation: Proposing an annual cash dividend and up to $500 million share repurchase; target to return at least $1 billion to shareholders by 2028.
• Leadership Transition: Supervisory Board transition with members stepping down after the Annual General Meeting.

Segment Performance

• Diagnostic Solutions: Sales rose 11% at constant exchange rates (CER), driven by QIAstat-Dx (37% growth) and QuantiFERON (16% growth).
• PCR Technologies: 14% CER growth, led by the QIAcuity digital PCR system and strong consumables sales.
• Sample Technologies: Down 1% CER, but preparing for new instrument launches (QIAssymphony Connect, QIAmini, QIAsprint Connect).
• Genomics and Next-Generation Sequencing: Down 2% CER, but QIAGEN Digital Insight (QDI) grew in high single-digits.
• Regional Performance: Americas grew 9% at CER, EMEA 8% at CER, Asia Pacific had a modest decline (driven by weak trends in China, but Japan saw solid single-digit growth).

Guidance

• Full Year 2025: Reaffirms 4% sales growth at CER (5% growth in core portfolio excluding discontinued products). Adjusted EPS target is $2.35 at CER (up $0.07 from initial outlook).
• Q2 2025: Targets net sales growth of at least 5% at CER and adjusted EPS of at least $0.60.

Risks

• Macro Environment: Cautious customer spending and evolving global trade dynamics pose challenges.
• Tariffs: Volatile tariff environment, but efforts to mitigate impact through inventory ramping and process changes.
• China Market: Weak trends in China, though it only represents 3-4% of total sales.

Question and Answer

• Q: Elaborate on QuantiFERON's Q1 acceleration A: Constant innovations, 4th generation product, global partnerships for automation, growing in multiple regions like North America, Europe, Middle East, Asia Pacific.
• Q: Guidance deceleration in H2 A: Prudent conservatism due to volatile macro environment, but will update net sales guidance if more visibility on macro trends is available.
• Q: Tariff exposure and mitigations A: Mitigated through inventory ramping, process changes, and working with customers; tariff impact is manageable.
• Q: Margin levers A: Efficiency programs, digitization, reorganization; expecting adjusted operating income margin above 30% by year-end.
• Q: Sample Tech growth and QuantiFERON China potential A: Sample Tech growing in high-value applications; QuantiFERON in China not a top priority, but leading in blood-based TB testing there.
• Q: PCR strength and QIAcuity A: PCR growing due to OEM sales and QIAcuity consumables; QIAcuity on track to reach $200 million in sales by 2028.
• Q: M&A pipeline and QIAstat outlook A: Active M&A pipeline; QIAstat expected to grow double-digits in 2025.
• Q: China market and QDI A: China market is complex and risky; QDI transitioning to SaaS, seeing growth in Q1 with both clinical and discovery activities improving.
• Q: Sample Tech automation and companion diagnostics A: Automation instruments bring value despite capital constraints; companion diagnostics growing double-digit, with extended pharma contracts and day 1 laboratory networks.